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Introduction: Forty percent of all breast cancer cases occur
among older women (age 65 years and older). This patient group is
underrepresented in the currently available studies, which obliges
physicians to take treatment decisions based on guidelines and
models that are not validated for older patients. With this study we
aim to provide insight in predictive factors for recurrence in clinically
favourable breast cancer, which can aid in individualizing treatment
for older breast cancer patients.
Objectives: To establish a predictive model for recurrence in
older breast cancer patients with a small breast tumour and a
clinically negative axilla.
Methods: From the Netherlands Cancer Registry, all patients aged
65 years and older with non-metastatic breast cancer, diagnosed
between 2003 and 2006, with a tumour with a maximum size of
5 cm, a clinical stage N0, and primary breast surgery, were included in
the analyses. First, we defined a set with most important predictors for
recurrence based on literature and expert-knowledge, comprising age,
T-stage (T1 or T2), histological grade (1 to 3), morphology (ductal,
lobular, mixed or other), oestrogen receptor (ER), progesterone
receptor (PR), Her2Neu receptor and multifocality. Primary endpoint
was 5-year recurrence, a combinedmeasure of locoregional and distant
recurrence. To take account for the competing risk of mortality, the
predictive value on the primary endpoint was analysed with Fine &
Gray analyses. Using backward elimination, predictors without statis-
tically significant predictive value were eliminated stepwise from the
model, until a remaining model was constituted with predictors that
had a statistically significant predictive value. All models were analysed
on discrimination by calculating the Area Under the Curve (AUC) of the
ROC-curve. Finally, all analyses were repeated in two age strata (65–74
and ≥75 years), to find out if predictors are the same for each age
category. Missing values were filled in using multiple imputation.
Results: Overall, 9183 patients were included in this study. After
backward eliminationwe remainedwith a predictivemodel comprising
four variables: age, T-stage, grade and ER. This model was able to
predict 5-years recurrencewith amean AUC of 0.69 (internal validation
after bootstrapping with 1000 replications). This AUC was the same as
for the full model. Stratification on age groups yielded the same
variables in the model for both strata.
Conclusion: In this national population-based study among older
breast cancer patients, we created a predictive model in which age,
T-stage, grade and ER can accurately predict 5-years recurrence risk.
Interestingly, the potential predictors morphology, Her2, multi-
focality and PR could be excluded from the model without losing
predictive value. This results in a model in which a physician can
predict the risk of recurrence based on a pre-operative biopsy, and
take treatment decisions on that basis. Future research should
determine the external validity of this prediction model, also taking
other factors such as comorbidity into account.
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Introduction: In upcoming decades, an increasing proportion of
breast cancer patients will be elderly. It has been assumed that
diagnosis at an earlier stage through screening programs could improve
prognosis. However, elderly may be at risk for over diagnosis due to
screening programs, and consequently unnecessarily at risk for possible
harmful effects of cancer treatment. In The Netherlands, the upper age
limit of the screening program was extended from 69 to 75 years in
1998. However, it remains unclear whether the mass screening
program has a beneficial effect in women aged 70 years and older.
Objectives: If a screening program is effective, it can be expected
that the incidence of early stage breast cancer increases, while the
incidence of advanced stage cancers decreases. According to several
studies, this is the most appropriate method to investigate the efficacy
of a screening program in population-based data, as studying mortality
rates as an indicator for the effect of screening programs can lead to
several forms of bias. Therefore, we investigated the effect of the
implementation of the screening program on the stage distribution of
incident breast cancer in women aged 70–75 years in the Netherlands.
Methods: The Netherlands Cancer Registry was used to include
all patients aged 70–75 years who were diagnosed between 1995
and 2011 with invasive or in situ breast cancer. Time trends of
incidence rates of different tumor stages were analyzed in linear
regression analyses with the incidence rate of both early stage (0, I
and II) and advanced stage (III and IV) breast cancer as the outcome,
and year of diagnosis as the independent variable.
Results: Overall, we included 25,414 patients aged 70–75 years at
diagnosis. The incidence of early stage tumors significantly increased
after extension of the upper age limit to 75 years in 1998 (260 cases per
100,000women in 1995 up to 382 cases per 100,000women in 2011, p
for trend= 0.03), while the number of advanced stage breast cancers
did not significantly change (59 cases per 100,000women in 1995 to 53
cases per 100,000 women in 2011, p for trend= 0.2).
Conclusion: The extension of the upper age limit to 75 years has not
led to a decrease of advanced stage breast cancer, while the number of
early stage tumors strongly increased. This implies that the effect of
screening in elderly women is limited and leads to a large proportion of
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